Articles tagged with Angiogenesis
Scientists identified SFLT-1 as the protein responsible for preventing blood vessel growth in corneas. Deactivating this protein allows angiogenesis to occur, leading to conditions such as macular degeneration and cancer. The discovery opens doors to new treatments by harnessing the natural anti-angiogenic properties of the eye.
Researchers at the University of Wisconsin-Madison have discovered a new compound that inhibits angiogenesis, a process essential for tumor growth. The compound, called NK-B, works by preventing the production of vascular endothelial growth factor and reducing receptor molecules that respond to VEGF.
Researchers discovered how Myc oncoprotein drives tumor angiogenesis in pancreatic cancer by inducing IL-1beta expression. Blocking IL-1beta activity can thwart tumor angiogenesis, offering experimental evidence for cancer drug therapies targeting this pathway.
Researchers have made significant breakthroughs in cancer vaccine development and cardiac health. A study on mice vaccinated with mimotopes inducing intermediate magnitude T cell responses found protection against tumor growth, while a study on Casq2-deficient mice revealed the mechanisms behind irregular heartbeats during exercise.
Researchers from the University of Pennsylvania School of Veterinary Medicine identified the role of microRNAs in promoting blood vessel growth, a process called angiogenesis. The findings suggest that these microRNAs might be targeted to slow down cancer cell growth.
A UK researcher found that VEGF promotes angiogenesis in macular degeneration, but also has an anti-angiogenic effect via SPARC. Controlling SPARC levels may be key to controlling angiogenesis in diseases like cancer. This discovery opens new avenues for treating diseases related to angiogenesis.
The study found two relapse peaks after surgery for breast cancer, with 20% of premenopausal patients relapsing within 10 months. Calculations predict that surgery-induced angiogenesis accelerates disease by two years and produces early deaths among screened young women.
Research reveals PTEN regulates VGF signaling, enhancing angiogenesis and accelerating tumor growth in mice. Individuals with mutated PTEN alleles are at risk for increased tumorigenic mutations and accelerated tumor growth due to enhanced angiogenesis.
Recent studies using transgenic mice have shown that overactive Akt1 can lead to cardiac dysfunction and hypertrophy. In contrast, Akt1 is critical for adaptive angiogenesis in the heart after ischemia. The research highlights the importance of understanding Akt1's role in regulating cardiovascular function.
Researchers discovered that tumor cells physically attach to a protein displayed on the surfaces of endothelial cells, triggering angiogenesis. The finding suggests a new anti-angiogenic strategy by blocking both secreted molecules and cell-to-cell contact.
Researchers have developed a marker to measure new blood vessel growth in tumors using positron emission tomography (PET) scanning and a fluorine-labeled glycopeptide. The marker, αvβ3 integrin, can identify tumors that express this marker, assess new vessel formation, and guide anti-angiogenic therapies.
Researchers found that naturally occurring proteins tumstatin, endostatin, and thrombospondin-1 inhibit angiogenesis, slowing tumor growth. The study's results suggest these proteins play a crucial role in controlling cancer progression, with potential therapeutic applications.
Scientists have discovered a way to manage angiogenesis by stimulating monocytes with GM-CSF, which produces soluble receptors that inhibit the formation of new blood vessels. The approach could provide a new therapeutic strategy for cancer treatment.
Researchers found that exercise increases VEGF production, which leads to an increase in capillaries within specific muscle fiber types. This change ultimately results in an anaerobic to aerobic shift in the affected muscle fibers.
Researchers used zebra fish to discover that nerves and blood vessels share similar guiding signals, crucial for therapeutic angiogenesis. This finding has significant implications for developing targeted forms of treatment for diseases like heart attacks.
Researchers found that S1P1 plays a crucial role in tumor angiogenesis, which is the formation of new blood vessels to supply nutrients to growing tumors. The study used RNA interference to block S1P1, demonstrating its importance in tumor growth and progression.
Scientists discover endothelial cells have higher levels of receptors for endostatin, which protects melanoma cells from angiogenesis inhibitors. This finding may lead to new cancer therapies targeting both angiogenesis and tumor cell vasculogenic mimicry.
Belgian researchers have discovered a revolutionary approach to angiogenesis by opening up tumor blood vessels, allowing for improved access to cancer drugs and radiotherapy. The key to this ability lies in the peptide endothelin-1, which stimulates tumor cell proliferation and causes arterioles to contract.
A novel compound called ZK-CDK has been shown to inhibit both tumour cell growth and angiogenesis in human cancer cells. The compound was tested on mice models and found highly efficacious, particularly in slow-growing hormone-independent breast and prostate tumours.
Researchers at UNC have identified a critical role for the flt-1 receptor in regulating sprouting angiogenesis, a key step in blood vessel formation. The study's findings may lead to new therapies for conditions like coronary heart disease and diabetes.
Dr. Judah Folkman, a pioneer in angiogenesis research, has been awarded the Novartis Award for Hypertension Research for his contributions to understanding how angiogenesis affects blood vessels leading to high blood pressure. His work has led to discoveries of new molecules and treatments for hypertension and cancer.
Scientists have identified a new class of proteins that promote angiogenesis, the formation of new blood vessels. Del-1 protein, discovered four years ago, has been found to be stable and continually stimulate angiogenesis. The researchers hope to use this knowledge to develop therapies that can inhibit angiogenesis in cancer.
Researchers at Winship Cancer Institute report that 2-methoxyestradiol (2ME2) inhibits tumor growth and angiogenesis by suppressing HIF. The compound targets microtubules, leading to the downregulation of HIF-1a and inhibition of tumor angiogenesis.
Researchers have discovered that combining endostatin and tumstatin may prove more effective in battling cancer than either one used separately. The two inhibitors work through distinct mechanisms, targeting different integrins to inhibit angiogenesis.
Researchers found that c-Myc is essential for tumor development by regulating blood vessel growth. The study suggests disrupting c-Myc may be a successful anti-angiogenic tool in cancer therapy, targeting tumors' vascular networks to slow growth.
Researchers combine a gene that shuts off angiogenesis with a nanoparticle that selectively targets cancer tumor cells, effectively cutting off their blood supply and killing the tumor. This approach shows strong regression of large tumors in every system tested.
Researchers have identified a molecular mechanism that controls a 'failsafe' device in endothelial cells, which marks them for apoptosis and blocks abnormal new blood vessel growth. This discovery may lead to the design of new anti-angiogenic drugs or improved existing treatments.
Researchers discovered that Nox1 enzyme generates reactive oxygen molecules that trigger angiogenesis and tumor growth. Inhibiting Nox1 activity or reducing hydrogen peroxide levels may decrease cancer cell growth and increase sensitivity to chemotherapy.
Researchers discover tumstatin protein inhibits angiogenesis by targeting a specific integrin molecule, preventing the growth of new blood vessels in tumors. The study provides new insights into the mechanism behind tumstatin's anti-angiogenic effects, paving the way for the development of more effective cancer drugs.
Scientists at Scripps Research Institute have discovered a fragment of the human protein TrpRS that inhibits angiogenesis, offering new hope for treatments of age-related macular degeneration and diabetic retinopathy. The truncated form of TrpRS appears to be more potent than existing antiangiogenic compounds.
Researchers found that EECP therapy increases levels of angiogenic factors, promoting the development of collateral vessels and improving blood flow. The study suggests EECP may be an alternative to invasive procedures for treating some Americans with angina.
Researchers warn that angiogenesis therapy could trigger growth in abnormal tissue, increase artery-clogging plaque, and stimulate inflammatory response. Despite these potential complications, the authors remain hopeful that the therapy will ultimately prove effective and safe.
Researchers have found that PR39 promotes angiogenesis by blocking the degradation of a key transcription factor, HIF-1alpha. The newly formed vessels were fully functional in mice studies, offering a promising tool for treating coronary artery disease and peripheral vascular disease.
A new MGH study has identified thrombospondin-2 (TSP-2) as a natural factor that inhibits tumor angiogenesis and growth in mouse models. The researchers found that TSP-2 completely stopped tumor growth when reintroduced into tumor cells, outperforming earlier anti-angiogenesis factors.
Researchers found that angiogenesis, the formation of new blood vessels, contributes to arthritic disease progression. Treatment with an integrin antagonist reduced joint swelling, pannus formation, and cartilage erosion in animal models.
Scientists have discovered that interleukin-12 (IL-12) can trigger the production of a protein called interferon-gamma (IFN-), which blocks tumor-induced angiogenesis. This finding suggests that tumor cells may be able to produce their own antiangiogenic elements, potentially leading to new cancer therapies.
Researchers at TSRI uncover a natural mechanism that regulates angiogenesis, a process involved in cancer growth. A recombinant protein fragment, PEX, is developed to block angiogenesis and tumor growth in an experimental model, offering a potentially novel therapeutic approach.